FIELD: medicine.
SUBSTANCE: invention relates to an imidazopyrimidine compound selected from a group of compounds specified in the claim. Invention also relates to a pharmaceutical composition containing a compound, a method of treating cancer mediated by EED protein activity, use of the compound for producing a drug for treating cancer mediated by EED protein activity, a method for inhibiting EED protein and a kit for treating cancer mediated by EED protein activity.
EFFECT: imidazopyrimidine compounds having EED inhibitory activity for treating EED-mediated diseases.
14 cl, 2 dwg, 7 tbl, 33 ex
Title | Year | Author | Number |
---|---|---|---|
N- (PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2744358C2 |
N-(PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2020 |
|
RU2831159C2 |
N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2722560C1 |
SULPHONAMIDE COMPOUND OR SALT THEREOF | 2017 |
|
RU2732572C2 |
ANTITUMOR AGENT | 2018 |
|
RU2770824C2 |
METHODS FOR TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH USE OF 2,4-PYRIMIDINEDIAMINE | 2013 |
|
RU2659777C2 |
SULPHONYLUREAS AND RELATED COMPOUNDS AND THEIR USE | 2016 |
|
RU2795512C2 |
HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2015 |
|
RU2711502C2 |
SUBSTITUTED CHROMANS | 2015 |
|
RU2718060C2 |
MDM2 PROTEIN DESTRUCTORS | 2017 |
|
RU2743432C2 |
Authors
Dates
2025-03-11—Published
2020-07-16—Filed